Drug Discovery World

MARCH 7, 2023

More research work focuses on dissecting the genetic architecture of other diseases such atrial fibrillation and arrhythmia,” Dr Saad says. More research work focuses on dissecting the genetic architecture of other diseases such atrial fibrillation and arrhythmia,” Dr Saad says.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Pharmaceutical Technology

MAY 17, 2023

The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets. Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing (XE) technologies to develop the medicines.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Pharmaceutical Technology

DECEMBER 22, 2022

The category crosses over with many of our other categories and can include new products, novel product features, new business practices, new marketing and sales strategies and more. This genetic-led approach will also aid in expediting the approval of new treatments.

Insulin 130

Insulin Production Development Genetics 130

Drug Discovery World

SEPTEMBER 14, 2023

Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. For Sanofi, second quarter 2023 sales growth of 3.3% AstraZeneca saw total revenue reach $22,295m, up 4% despite a decline of $2,181m from Covid-19 medicines. at CER and business EPS growth of 8.1% Specialty care grew 11.8% Vaccines were up 9.1%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

XTalks

DECEMBER 4, 2023

CAR T-cell therapies, which have been transformative in several blood cancers, involve extracting a patient’s own T cells, genetically modifying them with a chimeric antigen receptor (CAR) targeting specific proteins on cancer cells and then reinfusing them into the body. billion in sales in the first three quarters of 2023.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

XTalks

MARCH 8, 2022

With exciting new applications being developed in the areas of gene therapy, CRISPR and RNA editing, the contributions of women to these fields was highlighted in a piece we published last year on women scientists who paved the way forward in genetics.

Life Science 105

Life Science Gene Therapy DNA Vaccination 105

pharmaphorum

MAY 18, 2022

At UCB, we are trying to understand the whole spectrum of triggers causing epileptic seizures, from genetic factors, brain injury to stroke, cancer or other traumas,” Charl states. Charl believes we are witnessing the ‘decade of the brain’ with significant leaps in scientific understanding of disease pathways and genetic correlations.

Gene Therapy 92

Gene Therapy Gene Genetics Development 92

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca also wanted to endure shareholder value through global power and reach in sales and marketing, greater financial strategic flexibility and the creation of a stronger R&D platform for innovation-led growth. The merger of Astra and Zeneca aimed to improve the combined companies’ ability to deliver long term growth.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

The Pharma Data

OCTOBER 27, 2021

The San Nicolás site is a key component of a holistic strategy to accelerate the design of novel genetic combinations and produce high quality doubled haploid plants at scale. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 The Bayer brand stands for trust, reliability and quality throughout the world.

Development 40

Development Production Branding Life Science 40

XTalks

DECEMBER 13, 2023

In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. The year 2022 has proven to be a momentous period for Fulgent Genetics, marked by significant expansion of its product portfolio across various medical conditions.

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

OCTOBER 26, 2020

Sales. 50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). formerly known as Seattle Genetics, Inc.) Total Sales. 2019. .

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

SEPTEMBER 6, 2020

We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.”. billion in R&D and posted sales of CHF 61.5

FDA Approval 52

FDA Approval Medicine In-Vitro Genetics 52

XTalks

FEBRUARY 26, 2021

The controversy continues over profits, privacy of genetic information extracted from the cells and racial inequities in access to research and healthcare. As a result, members of Henrietta Lacks’ family were contacted for blood samples to genetically trace and identify the cells. Henrietta Lacks.

Scientist 69

Scientist Research Genetics Cosmetics 69

Drug Discovery World

OCTOBER 12, 2023

When it comes to the technologies driving drug discovery, she thinks that the ability to specifically edit regions of the genome using CRISPR/Cas9 is particularly revolutionary. She says: “We’re seeing an increase in companies seeking to raise their profile to achieve commercial partnerships to generate revenues or potential trade sales.”

Drugs 59

Drugs Life Science Genome Genomics 59

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. MELBOURNE, Australia, Jan. Quarterly Results Release Date and Webinar.

Genetics 52

Genetics Reagent Biobanking Production 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

The Pharma Data

NOVEMBER 10, 2020

Pacific Biosciences will not receive any proceeds from the sale of shares in the offering by the selling stockholder. A shelf registration statement relating to the shares of common stock was filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2020 and became automatically effective upon filing.

Sales 40

Sales Scientist Genome Genomics 40

pharmaphorum

MARCH 30, 2021

The Rare Answers tools are designed to deliver actionable data to physicians by analysing phenotypic and genomic data, incorporating precision software, medical information, and clinical insights. The future for rare disease diagnosis is looking a lot smarter, faster and quicker,” says Hartvig. The future of rare disease pharma.

Genetics 111

Genetics Marketing Development Genome 111

Drug Discovery World

NOVEMBER 8, 2023

Bredl’s poster looks at genetically engineered macrophages to disrupt the cold tumour microenvironment, and Sobczak’s covers deciphering the structural details of the recognition mode of cancer-associated glycoproteins by siglec receptors implicated in immune suppression in cancer.

Antibody 64

Antibody Engineer Protein Scientist 64

Delveinsight

JULY 20, 2021

Together with Seegene’s advanced technology and Bio-Rad’s solid client base, the two will be able to take the lead in the US market,” said Ho Yi, Chief Sales and Marketing Officer of Seegene. He further added that “The deal is expected to serve as the steppingstone for Seegene to secure its foothold in the US market.

FDA Approval 96

FDA Approval Marketing Trials Gene 96